Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(146 produtos)
- Bcr-Abl(102 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(245 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(79 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(268 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1431 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ProMMP-9 inhibitor-3c
CAS:<p>ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.</p>Fórmula:C18H20FN3O2SCor e Forma:SolidPeso molecular:361.43BPTQ
CAS:<p>BPTQ: DNA intercalator, halts cancer cell growth by blocking S/G2/M phases.</p>Fórmula:C17H16N4SPureza:98%Cor e Forma:SolidPeso molecular:308.4EGFR-IN-57
CAS:<p>EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.</p>Fórmula:C22H15N3O2SCor e Forma:SolidPeso molecular:385.44CPL304110
CAS:<p>CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.</p>Fórmula:C25H30N6O2Cor e Forma:SolidPeso molecular:446.54EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Cor e Forma:SolidPeso molecular:479.57VEGFR-2-IN-19
CAS:<p>VEGFR-2-IN-19 (15b) effectively inhibits VEGFR2, induces apoptosis, and increases oxidative stress, showing potential as an anticancer drug.</p>Fórmula:C21H19N3O2Cor e Forma:SolidPeso molecular:345.39EGFR-IN-52
CAS:<p>EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.</p>Fórmula:C19H18N4O3SCor e Forma:SolidPeso molecular:382.44JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Cor e Forma:SolidPeso molecular:543.61Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:434.43M1002
CAS:<p>M1002, a HIF-2 agonist, boosts HIF-2alpha/ARNT activation and alters HIF-281alpha PAS-B, working with PHD inhibitors.</p>Fórmula:C15H8F6N2O2SPureza:99.95%Cor e Forma:SolidPeso molecular:394.29ZK-261991
CAS:<p>ZK-261991 is an orally active inhibitor of VEGFR tyrosine kinase(IC50 of 5 nM, VEGFR2).</p>Fórmula:C24H25N7O2Pureza:98%Cor e Forma:SolidPeso molecular:443.5HSP90-IN-13
CAS:<p>HSP90-IN-13 (5k): potent HSP90 inhibitor, IC50 25.07 nM, targets EGFR/VEGFR-2/Topo-2, blocks MCF-7 G2/M cycle, induces apoptosis.</p>Fórmula:C26H21N5O3SCor e Forma:SolidPeso molecular:483.54Ilorasertib hydrochloride
CAS:<p>Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s:</p>Fórmula:C25H22ClFN6O2SPureza:98.45%Cor e Forma:SolidPeso molecular:525JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SCor e Forma:SolidPeso molecular:413.45UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Fórmula:C18H14ClN3O2Cor e Forma:SolidPeso molecular:339.78CAY10583
CAS:<p>CAY10583 is a selective BLT2 agonist that increases TGF-β1 and bFGF, promotes keratinocyte migration, accelerates wound healing in diabetic mice.</p>Fórmula:C25H25NO3Pureza:98%Cor e Forma:SolidPeso molecular:387.47EGFR-IN-56
CAS:<p>EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.</p>Fórmula:C23H22N4O3SCor e Forma:SolidPeso molecular:434.51NSC 33994
CAS:<p>NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.</p>Fórmula:C28H42N2O2Pureza:98%Cor e Forma:SolidPeso molecular:438.65JAK3/BTK-IN-6
CAS:<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Fórmula:C21H17BF3N5O3Cor e Forma:SolidPeso molecular:455.2EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PCor e Forma:SolidPeso molecular:759.68AFG206
CAS:AFG206 is the novel first-generation type II" FLT3 inhibitor."Fórmula:C20H19N3O2Cor e Forma:SolidPeso molecular:333.38TM-233
CAS:<p>TM-233 is an inhibitor of both JAK/STAT and proteasome activities that acts by inducing cell death in myeloma cells.</p>Fórmula:C25H20O4Pureza:98%Cor e Forma:SolidPeso molecular:384.42BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Fórmula:C27H22F3N5O2Cor e Forma:SolidPeso molecular:505.49VS 8
CAS:<p>VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.</p>Fórmula:C26H20F3N3O3Cor e Forma:SolidPeso molecular:479.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Cor e Forma:SolidPeso molecular:453.49BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Fórmula:C39H41N9O3Cor e Forma:SolidPeso molecular:683.8BCR-ABL-IN-2
CAS:<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Fórmula:C24H25Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:502.39MAX-40279 hemifumarate
CAS:<p>MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.</p>Fórmula:C48H50F2N12O6S2Cor e Forma:SolidPeso molecular:993.12JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SCor e Forma:SolidPeso molecular:593.11EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Cor e Forma:SolidPeso molecular:609.76TG 100801 Hydrochloride
CAS:<p>TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.</p>Fórmula:C33H31Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:616.54EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Cor e Forma:SolidPeso molecular:434.51NSC114792
CAS:<p>NSC114792 is a selective JAK3 inhibitor.</p>Fórmula:C26H32N4O2SPureza:98%Cor e Forma:SolidPeso molecular:464.62Atopaxar Hydrobromide
CAS:<p>Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H39BrFN3O5Pureza:98%Cor e Forma:SolidPeso molecular:608.54EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Cor e Forma:SolidPeso molecular:351.4Sch 13835
CAS:<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Fórmula:C15H10ClNO4SPureza:98%Cor e Forma:SolidPeso molecular:335.76EL-102
CAS:<p>EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.</p>Fórmula:C19H16N2O3S2Pureza:99.34%Cor e Forma:SolidPeso molecular:384.47SUN13837
CAS:<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Fórmula:C21H29N5O2Cor e Forma:SolidPeso molecular:383.49HS-438
CAS:<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Fórmula:C17H17N3O3SCor e Forma:SolidPeso molecular:343.4TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SCor e Forma:SolidPeso molecular:383.42EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Cor e Forma:SolidPeso molecular:453.49Nuvenzepine
CAS:<p>Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.</p>Fórmula:C19H20N4O2Pureza:98%Cor e Forma:SolidPeso molecular:336.39pan-HER-IN-1
CAS:<p>Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.</p>Fórmula:C19H14BrN5OCor e Forma:SolidPeso molecular:408.25FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Fórmula:C26H36N8OCor e Forma:SolidPeso molecular:476.62(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Fórmula:C17H19N3O2Cor e Forma:SolidPeso molecular:297.35AAE871
CAS:<p>AAE871 is a type I FLT3 inhibitor.</p>Fórmula:C24H34N8O2SCor e Forma:SolidPeso molecular:498.64EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SCor e Forma:SolidPeso molecular:658.64VEGFR2 Kinase Inhibitor II
CAS:<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Fórmula:C17H15BrN2OCor e Forma:SolidPeso molecular:343.22JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Cor e Forma:SolidPeso molecular:519.42Atopaxar
CAS:<p>Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H38FN3O5Pureza:97.07% - 98.07%Cor e Forma:SolidPeso molecular:527.63BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Fórmula:C29H23F3N6O3Cor e Forma:SolidPeso molecular:560.53GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Cor e Forma:SolidPeso molecular:596.74Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Cor e Forma:SolidPeso molecular:268.23EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Cor e Forma:SolidPeso molecular:569.67ALK-IN-21
CAS:<p>ALK-IN-21 (B10) inhibits ALK WT (IC50: 4.59nM), L1196M (2.07nM), G1202R (5.95nM); curbs Karpas299, H2228 cell growth; for ALCL research.</p>Fórmula:C35H45ClN6O6S4Cor e Forma:SolidPeso molecular:809.48FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Fórmula:C22H21N5O3Cor e Forma:SolidPeso molecular:403.43HZ-A-005
CAS:<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Fórmula:C25H23ClN6O2Cor e Forma:SolidPeso molecular:474.94JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Cor e Forma:SolidPeso molecular:522.55JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Cor e Forma:SolidPeso molecular:334.35BTK-IN-9
CAS:<p>BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.</p>Fórmula:C25H19N7O4Cor e Forma:SolidPeso molecular:481.46BMS-243117
CAS:<p>BMS-243117: Selective LCK inhibitor, IC50=1.1µM, inhibits T cell growth, promising for immunosuppression, arthritis, asthma treatment.</p>Fórmula:C20H21ClN4O2SCor e Forma:SolidPeso molecular:416.92MBM-55S
CAS:<p>MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.</p>Fórmula:C36H39FN6O10Pureza:99.37% - 99.89%Cor e Forma:SolidPeso molecular:734.73CGI560
CAS:<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Fórmula:C29H27N5OCor e Forma:SolidPeso molecular:461.56EGFR-IN-60
CAS:<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>Fórmula:C28H28Cl2N6OCor e Forma:SolidPeso molecular:535.47FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Cor e Forma:SolidPeso molecular:419.48Y 11
CAS:<p>focal adhesion kinase (FAK) inhibitor</p>Fórmula:C8H17BrN4OPureza:98%Cor e Forma:SolidPeso molecular:265.15Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidEGFR-IN-46
CAS:<p>EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.</p>Fórmula:C27H32F3N3O3Cor e Forma:SolidPeso molecular:503.56ZT55
CAS:<p>ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.</p>Fórmula:C17H16N2O3Cor e Forma:SolidPeso molecular:296.32JTV-519 free base
CAS:<p>JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmic</p>Fórmula:C25H32N2O2SPureza:98%Cor e Forma:SolidPeso molecular:424.6VEGFR-2-IN-24
CAS:<p>VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.</p>Fórmula:C28H23N3O6SCor e Forma:SolidPeso molecular:529.56FGFR4-IN-11
CAS:<p>FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.</p>Fórmula:C29H29N5O5Cor e Forma:SolidPeso molecular:527.57c-Met-IN-14
CAS:<p>c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.</p>Fórmula:C34H38ClFN4O7SCor e Forma:SolidPeso molecular:701.2ARQ 069
CAS:<p>ARQ 069 inhibits FGFR2 phosphorylation concentration-dependently (IC50: 9.7 µM), without affecting β-actin. Preferentially binds inactive FGFR1/2.</p>Fórmula:C18H15N3Pureza:98%Cor e Forma:SolidPeso molecular:273.33EGFR-IN-26
CAS:<p>EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.</p>Fórmula:C29H34N6O3Cor e Forma:SolidPeso molecular:514.62TRK/ALK-IN-1
<p>TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.</p>Fórmula:C31H35ClF2N8O2SCor e Forma:SolidPeso molecular:657.18FGFR3-IN-1
CAS:<p>FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).</p>Fórmula:C28H39N9O3SCor e Forma:SolidPeso molecular:581.73VA5 TG2 inhibitor
CAS:<p>VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.</p>Fórmula:C31H34N4O8Pureza:98%Cor e Forma:SolidPeso molecular:590.62TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Cor e Forma:SolidPeso molecular:310.35RET-IN-19
CAS:<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Fórmula:C28H28N6O4SCor e Forma:SolidPeso molecular:544.62EGFR-IN-59
CAS:<p>EGFR-IN-59: EGFR inhibitor, IC50 = 190 nM, induces apoptosis, cytotoxic to A549 cells (IC50 = 8.62 μM) and WI38 cells (IC50 = 52.6 μM). Use: Various cancers.</p>Fórmula:C27H23N5O4SCor e Forma:SolidPeso molecular:513.57EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SCor e Forma:SolidPeso molecular:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Fórmula:C13H11N3O2Cor e Forma:SolidPeso molecular:241.25RIPK2-IN-1
CAS:<p>RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM).</p>Fórmula:C23H27N5O3SCor e Forma:SolidPeso molecular:453.56Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Fórmula:C9H9NO3Cor e Forma:SolidPeso molecular:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OCor e Forma:SolidPeso molecular:415.25ALK-IN-22
CAS:<p>ALK-IN-22 suppresses ALK and mutants (IC50: 2.3-3.7 nM), hinders phosphorylation, and induces apoptosis in tumor studies.</p>Fórmula:C24H24ClN7O2Cor e Forma:SolidPeso molecular:477.95JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02AG-370
CAS:<p>AG 370, an indole tyrphostin, functions as a powerful inhibitor of PDGF-induced mitogenesis, demonstrating an IC50 of 20 μM.</p>Fórmula:C15H9N5Cor e Forma:SolidPeso molecular:259.27EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Cor e Forma:SolidPeso molecular:526.42CpCDPK1/TgCDPK1-IN-1
CAS:<p>CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.</p>Fórmula:C18H17N5Pureza:99.61%Cor e Forma:SolidPeso molecular:303.36FGFR3-IN-2
CAS:<p>FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor that inhibits FGFR3 (IC50: 4.1 nM) and VEGFR2 (IC50: 570 nM).</p>Fórmula:C28H39N9O4SCor e Forma:SolidPeso molecular:597.73CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36IHMT-TRK-284
CAS:<p>IHMT-TRK-284: Oral type II TRK inhibitor; targets TRKA, TRKB, TRKC (IC50s: 10.5, 0.7, 2.6 nM); selective and anti-tumor effective.</p>Fórmula:C25H27N7OSCor e Forma:SolidPeso molecular:473.59PDGFR-IN-1
CAS:<p>PDGFR-IN-1 is a platelet-derived growth factor receptor (PDGFR) inhibitor, strongly inhibiting PDGFRα and PDGFRβ, useful for studying solid tumors.</p>Fórmula:C25H30N8OPureza:99.13% - 99.49%Cor e Forma:SolidPeso molecular:458.56PDE5-IN-3
CAS:<p>PDE5-IN-3: Inhibits PDE5 (1.57 nM), EGFR (5.827 μM), Wnt pathway (1286.96 ng/mL), induces apoptosis, and has antitumor effects.</p>Fórmula:C21H14BrN5O2Cor e Forma:SolidPeso molecular:448.27TYK2-IN-12
CAS:<p>TYK2-IN-12: selective oral TYK2 inhibitor (Ki: 0.51 nM), blocks IL-12-induced IFNγ; IC50: human 2.7 µM, mouse 7.0 µM, used for psoriasis research.</p>Fórmula:C24H20F2N4O2Cor e Forma:SolidPeso molecular:434.44OD36 hydrochloride
CAS:<p>OD36 hydrochloride (OD-36 hydrochloride) is a potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 hydrochloride is a macrocyclic inhibitor that binds efficiently</p>Fórmula:C16H16Cl2N4O2Pureza:99.85%Cor e Forma:SolidPeso molecular:367.23Esuberaprost Sodium
CAS:<p>Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.</p>Fórmula:C23H27FN4O2Cor e Forma:SolidPeso molecular:410.48MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Cor e Forma:SolidPeso molecular:915.45
